Clinical Report: Coexpression of GITR Ligand Enhances Resistance of Anti-CD19 CAR-NK Cells
Overview
The study demonstrates that anti-CD19 CAR-NK cells coexpressing GITR ligand (GITRL) exhibit enhanced resistance to Treg-mediated immunosuppression and improved antitumor efficacy.
Background
Regulatory T cells (Tregs) significantly limit the effectiveness of immunotherapies, including CAR-cell therapies, by creating an immunosuppressive tumor microenvironment. Overcoming Treg-mediated suppression is essential for maximizing the therapeutic potential of engineered effector cells. The coexpression of GITRL on CAR-NK cells represents a promising strategy to counteract Treg suppression and enhance antitumor responses.
Data Highlights
Parameter
CAR19-GITRL-NK-92
CAR19-NK-92
Expansion
Superior
Standard
Cytotoxicity
Increased
Standard
Overall Survival
Longest
Shorter
Key Findings
CAR19-GITRL-NK-92 cells showed superior expansion and metabolic fitness compared to CAR19-NK-92 cells.
Enhanced cytotoxicity and cytokine secretion were observed against CD19⁺ targets in vitro.
RNA-Seq analysis revealed significant gene expression changes associated with immune activation and cytotoxicity.
In vivo studies demonstrated improved tumor control and overall survival with CAR19-GITRL-NK-92 cells.
GITRL expression mitigated Treg-mediated inhibition in CAR-NK cells.
Clinical Implications
The findings suggest that coexpressing GITRL on CAR-NK cells may enhance their efficacy against B-cell malignancies by overcoming Treg-mediated immunosuppression.
Conclusion
The study supports the efficacy of CAR19-GITRL-NK cells in enhancing CAR-NK cell therapies in treating B-cell leukemias and lymphomas.
by Dayane Schmidt, Sima Ebrahimabadi, Mariane Cariati Tirapelle, Camilly Melo Ferreira, Matheus Henrique dos Santos, Alison Felipe Biggi, Mara Elisama da Silva Januário, Rodrigo Tocantins Calado, Virginia Picanço-Castro
